Induction Therapy with Bortezomib Cyclophosphamide Dexamethasone and Conditioning with Lenalidomide for Al Renal Amyloidosis: Long-Term Follow Up

Greco Rosita*; Agata Mollica; Botta Cirino; Gentile Massimo; Enrica Martino; Papalia Teresa

**Greco Rosita*, Agata Mollica, Botta Cirino, Gentile Massimo, Enrica Martino and Papalia Teresa**

Volume5-Issue2
Dates: Received: 2024-02-14 | Accepted: 2024-02-25 | Published: 2024-02-28
Pages: 214-220

Abstract

Objectives: In our study we evaluated the long term efficacy of protocol with bortezomib in induction and lenalidomide in maintenance for AL renal Amyloidosis transplant-ineligible patients. Methods. A prospective analysis of 16 transplant-ineligible patients with histological diagnosis of renal amyloidosis. All patients had overt nephrotic syndrome. Bortezomib-based (CyBorD) regimen was used for 9 cycles. The patients with PRR were treated with Lenalidomide and dexamethasone.

Results: The mean age was 63±7aa and 7/16 were males. The amyloid deposits were FLC k in 6/16 and lambda in 10/16. At onset the mean proteinuria was 13.1±3.6gr/24h with average MDRD of 37.2ml/min. At onset 3 patients had Myeloma. 3/16 patients died for cardiac arrhythmia. CyBorD regimen was completed in 13/16. After 9 CyBorD cycles: 3/13 showed a Complete Renal Response (CRR) and Hematological Response (CHR); 10/13 showed a Partial Renal Response (PRR) and Partial Hemathological Response (PHR), but one died for Sepsi. The 9 patients in PRR were treated with Lenalidomide. After median 6 cycles 7/9 showed a CRR and CHR. Haemodialysis was started in 2/9. All the patients with CRR have been in remission for 30 months on average. Conclusion. Maintenance therapy with Lenalidomide is effective for complete and sustained renal remission.

FullText HTML FullText PDF DOI: 10.37871/jbres1884

Certificate of Publication

Copyright

How to cite this article

Rosita G, Mollica A, Cirino B, Massimo G, Martino E, Teresa P. Induction Therapy with Bortezomib Cyclophosphamide Dexamethasone and Conditioning with Lenalidomide for Al Renal Amyloidosis: Long-Term Follow Up. J Biomed Res Environ Sci. 2024 Feb 28; 5(2): 214-220. doi: 10.37871/jbres1884, Article ID: JBRES1884, Available at: https://www.jelsciences.com/articles/jbres1884.pdf

Subject area(s)

Liver

Public Health

Nephrology

References

Merlini G, Bellotti V. Molecular mechanisms of amyloidosis. N Engl J Med. 2003 Aug 7;349(6):583-96. doi: 10.1056/NEJMra023144. PMID: 12904524.
Comenzo RD. Current treatment options in oncology. Amyloidsis. 2006;7:225-236. doi: 10.1007/s11864-006-0015-8.
Gurung R, Li T. Renal Amyloidosis: Presentation, Diagnosis, and Management. Am J Med. 2022 Apr;135 Suppl 1:S38-S43. doi: 10.1016/j.amjmed.2022.01.003. Epub 2022 Jan 24. PMID: 35085515.
Milani P, Merlini G, Palladini G. Novel Therapies in Light Chain Amyloidosis. Kidney Int Rep. 2017 Nov 28;3(3):530-541. doi: 10.1016/j.ekir.2017.11.017. PMID: 29854961; PMCID: PMC5976806.
Obici L, Perfetti V, Palladini G, Moratti R, Merlini G. Clinical aspects of systemic amyloid diseases. Biochim Biophys Acta. 2005 Nov 10;1753(1):11-22. doi: 10.1016/j.bbapap.2005.08.014. Epub 2005 Sep 2. PMID: 16198646.
Nishi S, Alchi B, Imai N, Gejyo F. New advances in renal amyloidosis. Clin Exp Nephrol. 2008 Apr;12(2):93-101. doi: 10.1007/s10157-007-0008-3. Epub 2008 Jan 5. PMID: 18175051.
Bergesio F, Ciciani AM, Manganaro M, Palladini G, Santostefano M, Brugnano R, Di Palma AM, Gallo M, Rosati A, Tosi PL, Salvadori M; Immunopathology Group of the Italian Society of Nephrology. Renal involvement in systemic amyloidosis: an Italian collaborative study on survival and renal outcome. Nephrol Dial Transplant. 2008 Mar;23(3):941-51. doi: 10.1093/ndt/gfm684. Epub 2007 Oct 19. PMID: 17951308.
Ekelund L. Radiologic findings in renal amyloidosis. AJR Am J Roentgenol. 1977 Nov;129(5):851-3. doi: 10.2214/ajr.129.5.851. PMID: 410249.
Müller AM, Geibel A, Neumann HP, Kühnemund A, Schmitt-Gräff A, Böhm J, Engelhardt M. Primary (AL) amyloidosis in plasma cell disorders. Oncologist. 2006 Jul-Aug;11(7):824-30. doi: 10.1634/theoncologist.11-7-824. PMID: 16880241.
Kyle RA, Larson DR, Therneau TM, Dispenzieri A, Kumar S, Cerhan JR, Rajkumar SV. Long-Term Follow-up of Monoclonal Gammopathy of Undetermined Significance. N Engl J Med. 2018 Jan 18;378(3):241-249. doi: 10.1056/NEJMoa1709974. PMID: 29342381; PMCID: PMC5852672.
Merlini G, Stone MJ. Dangerous small B-cell clones. Blood. 2006 Oct 15;108(8):2520-30. doi: 10.1182/blood-2006-03-001164. Epub 2006 Jun 22. PMID: 16794250.
Leung N, Bridoux F, Hutchison CA, Nasr SH, Cockwell P, Fermand JP, Dispenzieri A, Song KW, Kyle RA; International Kidney and Monoclonal Gammopathy Research Group. Monoclonal gammopathy of renal significance: when MGUS is no longer undetermined or insignificant. Blood. 2012 Nov 22;120(22):4292-5. doi: 10.1182/blood-2012-07-445304. Epub 2012 Oct 9. PMID: 23047823.
Leung N. My patient with monoclonal gammopathy of undetermined significance has a kidney problem. Journal of Onco-Nephrology. 2017;1:18-23. doi: 10.5301/jo-n.5000005.
Selvanayagam JB, Hawkins PN, Paul B, Myerson SG, Neubauer S. Evaluation and management of the cardiac amyloidosis. J Am Coll Cardiol. 2007 Nov 27;50(22):2101-10. doi: 10.1016/j.jacc.2007.08.028. Epub 2007 Nov 13. Erratum in: J Am Coll Cardiol. 2011 Mar 29;57(13):1501. PMID: 18036445.
Kapoor P, Thenappan T, Singh E, Kumar S, Greipp PR. Cardiac amyloidosis: a practical approach to diagnosis and management. Am J Med. 2011 Nov;124(11):1006-15. doi: 10.1016/j.amjmed.2011.04.013. PMID: 22017778.
Wechalekar AD, Gillmore JD, Hawkins PN. Systemic amyloidosis. Lancet. 2016 Jun 25;387(10038):2641-2654. doi: 10.1016/S0140-6736(15)01274-X. Epub 2015 Dec 21. PMID: 26719234.
Schönland SO, Hegenbart U, Bochtler T, Mangatter A, Hansberg M, Ho AD, Lohse P, Röcken C. Immunohistochemistry in the classification of systemic forms of amyloidosis: a systematic investigation of 117 patients. Blood. 2012 Jan 12;119(2):488-93. doi: 10.1182/blood-2011-06-358507. Epub 2011 Nov 21. PMID: 22106346.
Benson MD, Dasgupta NR, Rao R. Diagnosis and Screening of Patients with Hereditary Transthyretin Amyloidosis (hATTR): Current Strategies and Guidelines. Ther Clin Risk Manag. 2020 Aug 14;16:749-758. doi: 10.2147/TCRM.S185677. PMID: 32884276; PMCID: PMC7434568.
Gertz MA, Comenzo R, Falk RH, Fermand JP, Hazenberg BP, Hawkins PN, Merlini G, Moreau P, Ronco P, Sanchorawala V, Sezer O, Solomon A, Grateau G. Definition of organ involvement and treatment response in immunoglobulin light chain amyloidosis (AL): a consensus opinion from the 10th International Symposium on Amyloid and Amyloidosis, Tours, France, 18-22 April 2004. Am J Hematol. 2005 Aug;79(4):319-28. doi: 10.1002/ajh.20381. PMID: 16044444.
Gertz MA, Comenzo R, Falk RH, Fermand JP, Hazenberg BP, Hawkins PN, Merlini G, Moreau P, Ronco P, Sanchorawala V, Sezer O, Solomon A, Grateau G. Definition of organ involvement and treatment response in immunoglobulin light chain amyloidosis (AL): a consensus opinion from the 10th International Symposium on Amyloid and Amyloidosis, Tours, France, 18-22 April 2004. Am J Hematol. 2005 Aug;79(4):319-28. doi: 10.1002/ajh.20381. PMID: 16044444.
Weiss BM, Wong SW, Comenzo RL. Beyond the plasma cell: emerging therapies for immunoglobulin light chain amyloidosis. Blood. 2016 May 12;127(19):2275-80. doi: 10.1182/blood-2015-11-681650. Epub 2016 Feb 23. PMID: 26907632.
Palladini G, Sachchithanantham S, Milani P, Gillmore J, Foli A, Lachmann H, Basset M, Hawkins P, Merlini G, Wechalekar AD. A European collaborative study of cyclophosphamide, bortezomib, and dexamethasone in upfront treatment of systemic AL amyloidosis. Blood. 2015 Jul 30;126(5):612-5. doi: 10.1182/blood-2015-01-620302. Epub 2015 May 18. PMID: 25987656.
Palladini G, Merlini G. What is new in diagnosis and management of light chain amyloidosis? Blood. 2016 Jul 14;128(2):159-68. doi: 10.1182/blood-2016-01-629790. Epub 2016 Apr 6. PMID: 27053535.
Milani P, Merlini G, Palladini G. Novel Therapies in Light Chain Amyloidosis. Kidney Int Rep. 2017 Nov 28;3(3):530-541. doi: 10.1016/j.ekir.2017.11.017. PMID: 29854961; PMCID: PMC5976806.
Reece DE, Hegenbart U, Sanchorawala V, Merlini G, Palladini G, Bladé J, Fermand JP, Hassoun H, Heffner L, Kukreti V, Vescio RA, Pei L, Enny C, Esseltine DL, van de Velde H, Cakana A, Comenzo RL. Long-term follow-up from a phase 1/2 study of single-agent bortezomib in relapsed systemic AL amyloidosis. Blood. 2014 Oct 16;124(16):2498-506. doi: 10.1182/blood-2014-04-568329. Epub 2014 Sep 8. PMID: 25202139; PMCID: PMC4199951.
Kastritis E, Wechalekar AD, Dimopoulos MA, Merlini G, Hawkins PN, Perfetti V, Gillmore JD, Palladini G. Bortezomib with or without dexamethasone in primary systemic (light chain) amyloidosis. J Clin Oncol. 2010 Feb 20;28(6):1031-7. doi: 10.1200/JCO.2009.23.8220. Epub 2010 Jan 19. PMID: 20085941.
Specter R, Sanchorawala V, Seldin DC, Shelton A, Fennessey S, Finn KT, Zeldis JB, Dember LM. Kidney dysfunction during lenalidomide treatment for AL amyloidosis. Nephrol Dial Transplant. 2011 Mar;26(3):881-6. doi: 10.1093/ndt/gfq482. Epub 2010 Aug 5. PMID: 20693160; PMCID: PMC3108346.
Weber DM, Chen C, Niesvizky R, Wang M, Belch A, Stadtmauer EA, Siegel D, Borrello I, Rajkumar SV, Chanan-Khan AA, Lonial S, Yu Z, Patin J, Olesnyckyj M, Zeldis JB, Knight RD; Multiple Myeloma (009) Study Investigators. Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America. N Engl J Med. 2007 Nov 22;357(21):2133-42. doi: 10.1056/NEJMoa070596. PMID: 18032763.
Furukawa M, Ohkawara H, Ogawa K, Ikeda K, Ueda K, Shichishima-Nakamura A, Ito E, Imai JI, Yanagisawa Y, Honma R, Watanabe S, Waguri S, Ikezoe T, Takeishi Y. Autocrine and Paracrine Interactions between Multiple Myeloma Cells and Bone Marrow Stromal Cells by Growth Arrest-specific Gene 6 Cross-talk with Interleukin-6. J Biol Chem. 2017 Mar 10;292(10):4280-4292. doi: 10.1074/jbc.M116.733030. Epub 2017 Jan 31. PMID: 28154173;